Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients
ConditionAsplenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPoitiers University Hospital
About this trial
Spleen could have been surgically removed for trauma, cancer, auto-immune disease, or to perform a diagnosis. Spleen could be non-functional due to radiotherapy or splenic artery embolism. These patients are at risks of infectious diseases due to encapsulated bacteria, cancer, and thromboembolism disease. The purpose of this study is to assess complications occurring in French patients without spleen and to implement new diagnostic tools for follow-up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥18 year-old
With asplenia due to splenectomy, splenic artery embolization or radiotherapy
Disqualifiers
Genetic asplenia including sick cell disease
Trial population
Patients \>18 years with acquired asplenia due to splenectomy, artery embolization, or spleen radiotherapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
6,000 Participants
are grouped into 1 trial groupGroup A: Single Group
Trial outcomes
Primary outcomes
1
Assessment of complication risk factors
Comparison between splenectomy and other type of asplenia for prevalence of infectious diseases, cancer, and thromboembolism disease
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Poitiers University Hospital
Lead sponsor
Pr Pierre BUFFET Institut National de la Transfusion Sanguine
Collaborator
Dr Edouard TUAILLON Département Bactériologie-Virologie/INSERM U1058 CHU de Montpellier
Collaborator
Source ClinicalTrials.gov